Sistemic Announces Customer Agreement with Cytori Therapeutics
Sistemic Ltd. ("Sistemic"), a leading provider of microRNA-based problem-solving services and kit-based products, has fo…
Sistemic Ltd. ("Sistemic"), a leading provider of microRNA-based problem-solving services and kit-based products, has fo…
Cytori Therapeutics (NASDAQ: CYTX) has obtained approval to sell the Celution® 800 System in Russia for various medical…
Cytori Therapeutics (NASDAQ: CYTX) has received an Investigational Device Exemption (IDE) approval from the U.S. FDA to…
Cytori Therapeutics (NASDAQ: CYTX) announced today the publication of previously reported six-month outcomes from APOLLO…
Cytori Therapeutics, Inc. (NASDAQ: CYTX) today announced that results from an economic analysis carried out by the UK NH…
Cytori Therapeutics, Inc. (NASDAQ:CYTX) reports that surgeons from North Tees and Hartlepool NHS Foundation Trust have p…
The US Patent and Trademark Office issued a new patent (US Patent No. 7,887,795; direct link to USPTO site - http://bit.…
Cytori (NASDAQ: CYTX) received approval from The Netherlands to initiate a pivotal European trial, named ADVANCE, to inv…
Preclinical data was published today on research performed by Cytori Therapeutics (NASDAQ:CYTX) showing adipose (fat)-de…
Cytori Therapeutics (NASDAQ: CYTX) has received U.S. Patent No. 7,771,716 (the '716 patent) for Celution(R) System based…